CASI Pharmaceuticals, Inc. (CASI) Form 20-F — May 15, 2026
CASI Pharmaceuticals reported a net loss of $48.1 million for the year ended December 31, 2025, with revenue declining to $20.7 million. The company disclosed an accumulated deficit of $748.1 million and only $5.6 million in cash, leading to explicit going-concern language stating that recurring operating losses raise substantial doubt about its ability to continue as a going concern. The company faces severe liquidity constraints with net current liabilities of $36.2 million.
Key figures
- Revenue
- 20700000
- Total Debt
- 0
- Cash Position
- 5600000
- Shares Outstanding
- 20555873
- China asset sale price
- 20000000
- Going private proposal price
- 1.15
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.